NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

A new treatment, lisocabtagene maraleucel, has been approved for NHS use, benefiting hundreds of blood cancer patients in England.

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

An innovative new treatment is set to benefit hundreds of people in England with aggressive blood cancer after it was given ...